← Human Trials & Peer-Reviewed Studies
Low acceptance of osteoanabolic therapy with parathyroid hormone in patients with fragility fracture of the pelvis in routine clinical practice: a retrospective observational cohort study
Plain-language guide to PMID 31332508 (2020): randomized observational study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 79 patients.
Key Facts
- PMID
- 31332508
- Journal
- Archives of orthopaedic and trauma surgery
- Year
- 2020
- Study type
- Observational Study
- Authors
- Suhm N et al. (6 authors)
- DOI
- 10.1007/s00402-019-03241-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide and Parathyroid Hormone (PTH 1-84) in this observational study publication.
The purpose of the presented study was to evaluate if similar results can be achieved with comprehensive PTH therapy in routine clinical practice.
Why It Was Studied
A recent randomized controlled trial has reported full patient compliance and no adverse events from therapy with parathyroid hormone (PTH) for osteoporosis and accelerated healing of fragility fractures of the pelvis.
The researchers hypothesised that patients' burden of PTH therapy is underestimated in the literature.
Who Took Part
The study group was 79 patients.
By PubMed's age tags, the people studied were older adults, both men and women.
Osteoanabolic PTH therapy was recommended to 79 patients suffering from an acute fragility fracture of the pelvis (FFP).
Adverse events and effects potentially related to the therapy with bone-active drugs were documented as exploratory outcomes.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
Case finding, initiation of therapy and follow-up were performed by a fracture liaison service team.
Primary outcome was PTH initiation rate.
What Was Measured
PubMed files the paper under topics including Anabolic Agents, Bone Density Conservation Agents, Hip Fractures, Osteoporosis, Osteoporotic Fractures, Patient Compliance and Teriparatide.
The authors tagged it with the keywords Fragility fracture of the pelvis and Osteoanabolic therapy.
What This Means in Plain Language
The paper is a randomized study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 79 patients.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2020 (Archives of orthopaedic and trauma surgery), a journal based in Germany.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.